You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,708,397


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,708,397
Title:Treatment of vasculoproliferative conditions with Lrg1 antagonists
Abstract: This invention relates to the field of molecular physiology. Specifically, this invention relates to the treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to treat vasculoproliferative conditions.
Inventor(s): Greenwood; John (London, GB), Moss; Stephen (London, GB), Wang; Xiaomeng (London, GB)
Assignee:
Application Number:14/312,593
Patent Claims:1. A method of inhibiting vasculoproliferation comprising administering to a patient in need thereof an effective amount of an antagonist of Lrg1, wherein said antagonist comprises a short interfering RNA (siRNA) that targets Lrg1 RNA to knock down Lrg1 expression and so reduce Lrg1 function.

2. The method according to claim 1, wherein the vasculoproliferation is selected from a group consisting of neovascularisation, vascular endothelial cell proliferation, angiogenesis, telangiectasia, diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, macular telangiectasia, age-related macular degeneration or choroidal neovascularization.

3. The method according to claim 1, wherein the Lrg1 antagonist is for use in combination with an antiangiogenic compound.

4. The method according to claim 3, wherein the antiangiogenic compound is an antagonist of vascular endothelial growth factor (VEGF).

5. The method according to claim 4, wherein the antagonist of VEGF is an anti-VEGF antibody.

6. The method according to claim 4, wherein the antagonist of VEGF is a receptor-based VEGF trap.

7. The method according to claim 4, wherein the antagonist of VEGF is Aflibercept.

8. The method according to claim 4, wherein the antagonist of VEGF is Avastin or Lucentis.

Details for Patent 9,708,397

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2029-09-04
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 06/30/2006 ⤷  Try a Trial 2029-09-04
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 08/10/2012 ⤷  Try a Trial 2029-09-04
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 10/13/2016 ⤷  Try a Trial 2029-09-04
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 03/20/2018 ⤷  Try a Trial 2029-09-04
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 11/18/2011 ⤷  Try a Trial 2029-09-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.